{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:58:49Z","timestamp":1785466729137,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12328-026-02314-3","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:55:57Z","timestamp":1779688557000},"page":"976-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gallbladder cancer with dual genetic variants of PMS2 and BRCA2: a case report"],"prefix":"10.1007","volume":"19","author":[{"given":"Ryohei","family":"Sumii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0557-9125","authenticated-orcid":false,"given":"Shizuma","family":"Omote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Omote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Toyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"2314_CR1","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: Breast, ovarian. version 1.2025."},{"key":"2314_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/jmg.36.11.801","volume":"36","author":"HT Lynch","year":"1999","unstructured":"Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer (Lynch syndrome). J Med Genet. 1999;36:801\u201318. https:\/\/doi.org\/10.1136\/jmg.36.11.801.","journal-title":"J Med Genet"},{"key":"2314_CR3","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402\u201316. https:\/\/doi.org\/10.1001\/jama.2017.7112.","journal-title":"JAMA"},{"key":"2314_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1158\/1055-9965.EPI-16-0693","volume":"26","author":"AK Win","year":"2017","unstructured":"Win AK, Jenkins MA, Dowty JG, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2017;26:404\u201312. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0693.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2314_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41467-018-06581-8","volume":"9","author":"Y Momozawa","year":"2018","unstructured":"Momozawa Y, Iwasaki Y, Parsons MT, et al. Germline pathogenic variants of cancer-susceptibility genes in 7,055 Japanese individuals. Nat Commun. 2018;9:482.","journal-title":"Nat Commun"},{"key":"2314_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jhep.2022.09.025","volume":"78","author":"Y Okawa","year":"2023","unstructured":"Okawa Y, Iwasaki Y, Johnson TA, et al. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J Hepatol. 2023;78:333\u201342. https:\/\/doi.org\/10.1016\/j.jhep.2022.09.025.","journal-title":"J Hepatol"},{"issue":"1","key":"2314_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-01231-9","volume":"5","author":"K Mizukami","year":"2025","unstructured":"Mizukami K, Usui Y, Iwasaki Y, et al. Pan-cancer prevalence, risk, and clinical and demographic characteristics of Lynch syndrome-associated variants in BioBank Japan. Commun Med. 2025;5(1):522. https:\/\/doi.org\/10.1038\/s43856-025-01231-9.","journal-title":"Commun Med"},{"key":"2314_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s10038-017-0347-1","volume":"63","author":"Y Yamaguchi-Kabata","year":"2018","unstructured":"Yamaguchi-Kabata Y, Yasuda J, Tanabe O, et al. Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals. J Hum Genet. 2018;63:213\u201330. https:\/\/doi.org\/10.1038\/s10038-017-0347-1.","journal-title":"J Hum Genet"},{"issue":"6","key":"2314_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/(sici)1097-0215(20000315)85:6<796::aid-ijc10>3.0.co;2-l","volume":"85","author":"A Borg","year":"2000","unstructured":"Borg A, Isola J, Chen J, et al. Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma. Int J Cancer. 2000;85(6):796\u2013800. https:\/\/doi.org\/10.1002\/(sici)1097-0215(20000315)85:6%3c796::aid-ijc10%3e3.0.co;2-l.","journal-title":"Int J Cancer"},{"issue":"2","key":"2314_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.bjc.6601424","volume":"90","author":"I Thiffault","year":"2004","unstructured":"Thiffault I, Hamel N, Pal T, et al. Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. Br J Cancer. 2004;90(2):483\u201391. https:\/\/doi.org\/10.1038\/sj.bjc.6601424.","journal-title":"Br J Cancer"},{"key":"2314_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-531","volume":"12","author":"K Kast","year":"2012","unstructured":"Kast K, Neuhann TM, G\u00f6rgens H, et al. Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer. BMC Cancer. 2012;12:531. https:\/\/doi.org\/10.1186\/1471-2407-12-531.","journal-title":"BMC Cancer"},{"issue":"3","key":"2314_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.gynor.2012.03.001","volume":"2","author":"P Gong","year":"2012","unstructured":"Gong P, Charles S, Rosenblum N, et al. A case of endometrial cancer in the context of a BRCA2 mutation and double heterozygosity for Lynch syndrome. Gynecol Oncol Case Rep. 2012;2(3):69\u201372. https:\/\/doi.org\/10.1016\/j.gynor.2012.03.001.","journal-title":"Gynecol Oncol Case Rep"},{"issue":"3","key":"2314_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10151-013-1030-y","volume":"18","author":"M Pedroni","year":"2014","unstructured":"Pedroni M, Di Gregorio C, Cortesi L, et al. Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors. Tech Coloproctol. 2014;18(3):285\u20139. https:\/\/doi.org\/10.1007\/s10151-013-1030-y.","journal-title":"Tech Coloproctol"},{"issue":"2","key":"2314_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10549-020-05569-7","volume":"180","author":"S Sorscher","year":"2020","unstructured":"Sorscher S, Ansley K, Delaney SD, et al. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1). Breast Cancer Res Treat. 2020;180(2):511\u20134. https:\/\/doi.org\/10.1007\/s10549-020-05569-7.","journal-title":"Breast Cancer Res Treat"},{"key":"2314_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00560","volume":"6","author":"M Ozer","year":"2022","unstructured":"Ozer M, Ranganathan M, Lecomte N, et al. Concurrent germline BRCA1\/2 and mismatch repair mutations in young-onset pancreatic and colorectal cancer: the importance of comprehensive germline and somatic characterization to inform therapeutic options. JCO Precis Oncol. 2022;6:e2100560. https:\/\/doi.org\/10.1200\/PO.21.00560.","journal-title":"JCO Precis Oncol"},{"key":"2314_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/s10038-023-01178-6","volume":"68","author":"R Harada","year":"2023","unstructured":"Harada R, Matsubayashi H, Kiyozumi Y, et al. A Japanese case of ovarian mucinous adenocarcinoma with germline double variants of MSH2 and BRCA2. J Hum Genet. 2023;68:783\u20137. https:\/\/doi.org\/10.1038\/s10038-023-01178-6.","journal-title":"J Hum Genet"},{"key":"2314_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.581982","volume":"7","author":"H Zheng","year":"2020","unstructured":"Zheng H, Yuan M, Wu H, et al. Case report: Double germline mutations in BRCA1 and MSH2 in a patient with mixed serous-endometrioid endometrial carcinoma. Front Med. 2020;7:581982. https:\/\/doi.org\/10.3389\/fmed.2020.581982.","journal-title":"Front Med"},{"key":"2314_CR18","doi-asserted-by":"publisher","first-page":"5879510","DOI":"10.1155\/2025\/5879510","volume":"2025","author":"MM Puglisi","year":"2025","unstructured":"Puglisi MM, et al. Germline BRCA2 mutation and Lynch syndrome in a patient with multiple primary malignancies. Case Rep Oncol Med. 2025;2025:5879510. https:\/\/doi.org\/10.1155\/2025\/5879510.","journal-title":"Case Rep Oncol Med"},{"key":"2314_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jamaoncol.2015.4771","volume":"2","author":"J Whitworth","year":"2016","unstructured":"Whitworth J, Skytte A-B, Sunde L, et al. Multilocus inherited neoplasia alleles syndrome: A case series and review. JAMA Oncol. 2016;2:373\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4771.","journal-title":"JAMA Oncol"},{"key":"2314_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41431-021-01013-6","volume":"30","author":"A McGuigan","year":"2022","unstructured":"McGuigan A, Whitworth J, Andreou A, et al. Multilocus Inherited Neoplasia Allele Syndrome (MINAS): An update. Eur J Hum Genet. 2022;30:265\u201370. https:\/\/doi.org\/10.1038\/s41431-021-01013-6.","journal-title":"Eur J Hum Genet"},{"key":"2314_CR21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial. Nat Med. 2018;24:628\u201337. https:\/\/doi.org\/10.1038\/s41591-018-0009-7.","journal-title":"Nat Med"},{"key":"2314_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"key":"2314_CR23","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1500596.","journal-title":"N Engl J Med"},{"key":"2314_CR24","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"key":"2314_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0479","volume":"8","author":"Y Momozawa","year":"2022","unstructured":"Momozawa Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8:871\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0479.","journal-title":"JAMA Oncol"},{"key":"2314_CR26","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/jhbp.1063","volume":"29","author":"S Takamizawa","year":"2022","unstructured":"Takamizawa S, Morizane C, Tanabe N, et al. Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome. J Hepatobiliary Pancreat Sci. 2022;29:377\u201384. https:\/\/doi.org\/10.1002\/jhbp.1063.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2314_CR27","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Colorectal. Version 2.2023."},{"key":"2314_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94\u2013101. https:\/\/doi.org\/10.1038\/s41586-020-1943-3.","journal-title":"Nature"},{"key":"2314_CR29","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598\u2013608. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0386.","journal-title":"Mol Cancer Ther"},{"key":"2314_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"key":"2314_CR31","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","volume":"171","author":"BB Campbell","year":"2017","unstructured":"Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042-56.e10. https:\/\/doi.org\/10.1016\/j.cell.2017.09.048.","journal-title":"Cell"},{"key":"2314_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-015-0123-z","volume":"8","author":"GL Ryland","year":"2015","unstructured":"Ryland GL, Doyle MA, Goode D, et al. Loss of heterozygosity: what is it good for? BMC Med Genomics. 2015;8:45. https:\/\/doi.org\/10.1186\/s12920-015-0123-z.","journal-title":"BMC Med Genomics"},{"key":"2314_CR33","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4.","journal-title":"Lancet"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02314-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02314-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:05:43Z","timestamp":1785463543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02314-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2314"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02314-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}